Company intelligence / Profile preview

MEGA BIOPHARMA

Crosne, Île-de-France, Francemegabiopharma.com ↗

Ownership: Private
Employees: ~19
Development stage: Commercial

Overview

MEGA BIOPHARMA’s main product is Bionacre®, a bioactive bone graft material that promotes bone healing through both osteoconductive and osteoinductive mechanisms. It is fully bioresorbable with optimized resorption kinetics supporting new bone growth without secondary surgery. The product has shown scientifically proven results in bone and skin repair domains.

Therapeutic areas: OtherDermatology
Modalities: Marine-derived biomaterials for medical useBone graft materials derived from nacre (mother-of-pearl)Tissue regeneration technology using bioactive compounds from seashells
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Bionacre BG

Commercial

Indications: Bone defects, Dental surgery, Orthopedic surgery

Partnerships

collaboration with NAMSA for de-risking dental technology development

Beyond the preview

Go deeper on MEGA BIOPHARMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEGA BIOPHARMA.